Phase 2a Open Label Study to Assess the Efficacy and Safety of Subcutaneous 15mg AKB-9778 Administered Twice Daily for 84 Days in Subjects With Retinal Vein Occlusion

Trial Profile

Phase 2a Open Label Study to Assess the Efficacy and Safety of Subcutaneous 15mg AKB-9778 Administered Twice Daily for 84 Days in Subjects With Retinal Vein Occlusion

Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2017

At a glance

  • Drugs AKB 9778 (Primary)
  • Indications Retinal vein occlusion
  • Focus Therapeutic Use
  • Sponsors Aerpio Pharmaceuticals
  • Most Recent Events

    • 23 May 2017 Status changed from recruiting to completed.
    • 13 Mar 2017 According to Aerpio Pharmaceuticals 8-K, this trial was initiated by Aerpio Therapeutics, but later on this company's name changed to Aerpio pharmaceuticals.
    • 25 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top